You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to September 2024

AbstractFullPdf
Nov 2021372025
Dec 2021244044
Jan 2022114081
Feb 202256041
Mar 2022180056
Apr 2022100042
May 202266050
Jun 2022112063
Jul 202276039
Aug 202264037
Sep 2022126063
Oct 202284044
Nov 202296030
Dec 202286031
Jan 202364021
Feb 202386027
Mar 202386025
Apr 202372028
May 202364030
Jun 202386021
Jul 202352036
Aug 202370016
Sep 202376014
Oct 2023100015
Nov 2023100025
Dec 202396016
Jan 20243407
Feb 20246209
Mar 2024102034
Apr 2024142020
May 202478027
Jun 202498018
Jul 202494021
Aug 20248405
Sep 2024150015
Total357201076